MET, a receptor tyrosine kinase (RTK), is activated by ligands such as hepatocyte growth factor (HGF)/scattering factor (SF) and drives key processes in tumor progression, including invasion, proliferation, and angiogenesis. The gene discussed is HGF; the disease is neoplasm.